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Introduction
The modiﬁcation of proteins by post-
translational changes represents a key
regulatory mechanism of signal trans-
duction that allows a rapid and
dynamic cellular response to distinct
environmental stimuli as well as to intracellular signals (Deribe
et al, 2010). The addition of chemical moieties or proteins alters
the structure, localization, activity and thereby the function of
the modiﬁed protein. Once a protein is modiﬁed by a post-
translational modiﬁcation (PTM), the signal is decoded by
unique recognition motifs within the same protein or in others
leading tochanges intheconstituents ofmolecular complexesin
the cells (Seet et al, 2006). The dynamic processes of assembly
and disassembly of complexes mediated by PTMs form the
central core of the signal transduction machinery driving
various cellular functions. Recent studies have revealed that
more than 200 forms of protein modiﬁcations are present in the
cells and we have only started to understand the biological
signiﬁcance of the complex cross talk between them in
regulating various processes (Mann & Jensen, 2003). In the
early 1980s, covalent conjugation of ubiquitin, a 76 amino acid
polypeptide of the family of ubiquitin-like (UBL) proteins, to the
target proteins was linked to their degradation via the
proteasome (Hershko & Ciechanover, 1998). Today, ubiquitin
is recognized as a most versatile form of PTM as it can be
conjugated either as a monomer or as polyubiquitin chains of
various kinds (Ikeda & Dikic, 2008). Similar to other PTMs such
as phosphorylation or acetylation, ubiquitylation is a reversible
and usually inducible event. Conjugation of ubiquitin to a
substrate protein leads to various consequences in the cell such
as proteolytical degradation by proteasomes or lysosomes,
altered subcellular localization or activity and interaction with
other proteins (Bergink & Jentsch, 2009; Hirsch et al, 2009;
Mukhopadhyay & Riezman, 2007; Varshavsky, 2005; Vucic
et al, 2011). As ubiquitylation represents a general regulatory
mechanism of signal transduction, it is not surprising that
misregulationofubiquitinsignallingisassociatedwithinitiation
and progression of various human diseases including inﬂam-
mation and cancer (Hoeller & Dikic, 2009). Thus, targeting
components of the ubiquitin machinery has evolved as a valid
strategy for therapeutic interventions. The clinical successes of
the proteasome inhibitor bortezomib (PS-341) in treating
haematological malignancies such as multiple myeloma and
mantle-cell lymphoma has encouraged scientists to further
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Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the
most crucial post-translational modiﬁcations controlling virtually all cellular pro-
cesses. What was once regarded as a mere signal for protein degradation has turned
out to be a major regulator of molecular signalling networks. Deregulation of
ubiquitin signalling is closely associated with various human pathologies. Here,
we summarize the current knowledge of ubiquitin signalling in immune deﬁciencies
and cancer as well as the available therapeutic strategies targeting the ubiquitin
system in combating these pathogenic conditions.
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kinds of cancer as well (Chen et al, 2011). In this review, we will
provide the basic description of the ubiquitin machinery,
summarize the role of ubiquitin in molecular medicine
approaches in the ﬁeld of immune disorders and cancer as
well as the current therapeutic strategies targeting these
pathologies.
Principles of ubiquitin signalling
The attachment of ubiquitin to target-proteins, i.e. the
ubiquitylation process, usually occurs on lysine residues and
proceeds via a three-step procedure involving three different
types of enzymes. In the ﬁrst step, an E1-activating enzyme
forms a thioester bond with ubiquitin in an ATP-dependent
manner. In the second step, ubiquitin is transferred to an E2
enzyme by trans-thiolation (Schulman & Harper, 2009). Finally,
the E3 ubiquitin ligases catalyze the transfer of ubiquitin from
theE2tothee-aminogroupofalysineresidueinatarget-speciﬁc
manner (Fig 1). The human genome encodes two E1 enzymes,
37 E2 enzymes and more than 600 E3 ligases. The three classes
of E3 ligases (RING, HECT, U-box) are responsible for the
recognition of substrates (Grabbe et al, 2011). RING-type
ubiquitin E3 ligases contain the RING domain, a zinc-binding
protein–protein interaction motif, while HECT E3 ligases
harbour a motif with a catalytic Cys residue, which becomes
part of a thioester intermediate when ubiquitin is transferred to
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Glossary
DUB
Deubiquitinases are proteases responsible for cleaving ubiquitin from
substrate proteins. They also process ubiquitin precursors to maintain
ubiquitin homeostasis.
E3 ligases
Enzymes responsible for catalysing the transfer of ubiquitin to a lysine
residue in the substrate protein.
F-box
A protein domain of  50 amino acids involved in mediating protein–
protein interactions. F-box proteins function as substrate recognition
subunits in cullin-ring ubiquitin ligases.
HECT
A protein domain present in many ubiquitin ligases. These domains possess
a catalytic Cys residue that forms a thioester intermediate during the
conjugation of ubiquitin to the substrate protein.
Proteasome
A multisubunit protein complex responsible for ATP-dependent
degradation of ubiquitin tagged proteins. Inhibitors of proteasome
are pursued as cancer chemotherapeutic drugs to kill tumour
cells.
RING
A zinc-binding protein–protein interaction motif that binds to the
E2-ubiquitin thioester and thereby promotes the conjugation of ubiquitin
to substrate proteins.
UBD
A short ( 40 amino acids) sequence motif that mediates ubiquitin
binding.
Ubiquitylation
A posttranslational modification where ubiquitin is covalently conjugated
in a three step enzymatic cascade to a lysine residue in the modified
protein. Ubiquitin conjugated proteins are recognized by ubiquitin
receptors, which determine the functional outcomes.
Ub Ub Ub Ub
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Figure 1. Principles of ubiquitin signalling. Ubiquitylation is mediated by the sequential activity of a set of enzymes including activating (E1), conjugating (E2)
and ligating (E3) enzymes. This leads to the conjugation of monoubiquitin or polyubiquitin chains of different lengths and link ages to target proteins. Depending
on thedifferents types of ubiquitin chains, proteins are subsequently degraded via theproteasome or participate in various cell ularfunctions including signalling,
DNA repair or endocytosis. See text for more details.
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emerged as key mediators of chain assembly by controlling the
switch from ubiquitin chain initiation to elongation and by
regulating the processivity of chain formation as well as the
topology of assembled chains (Grabbe et al, 2011). Further,
deubiquitinases(DUBs,approximately100)addanotherlayerof
complexity by editing or removing ubiquitin from substrates
(Clague et al, 2012; Haglund & Dikic, 2005). Proteins can be
modiﬁed with an addition of one ubiquitin molecule on a single
lysine (monoubiquitylation) or on several lysines (multi-
monoubiquitylation). This type of ubiquitin modiﬁcation has
been associated with processes like deoxyribonucleic acid
(DNA) repair, histone regulation and endocytosis (Haglund &
Dikic, 2005). Further, ubiquitin itself possesses seven lysines
(6, 11, 27, 29, 33, 48, 63), which could serve as an acceptor for
ubiquitin chains (Fig 1). Recent studies revealed that head-to-
tail linear ubiquitin chains (M1-linked) could also be synthe-
sized in vivo by dedicated E3 ubiquitin ligases (Iwai &
Tokunaga, 2009; Walczak et al, 2012). The lysine 48-linked
chain is the prototypic ubiquitin signal for degradation via the
proteasome. By comparison, linkage through lysine 63 or M1
(linear) chains represents a typical non-degradative modiﬁca-
tion primarily contributing to assemblage of protein complexes
and signal transduction (Ikeda & Dikic, 2008). The physiological
roles of atypical ubiquitin chains are just emerging and this
remarkable diversity inﬂuences almost all aspects of cellular
physiology. Ubiquitin is recognized by more than 20 kinds of
ubiquitin binding domains, which exhibit speciﬁcity for the
mode of ubiquitylation and bind non-covalently to ubiquitin
(Fig 1)(Dikic etal, 2009). These UBL receptorsﬁnally determine
the functional outcomes of the entire process.
Ubiquitin signalling in immune disorders and
inflammation
Protein ubiquitylation has also emerged as one of the key
mechanisms that control innate or adaptive immune responses.
Ubiquitin signalling has a broad role in these processes by
controlling the development of the immune system, as well as
several phases of the immune response, ranging from initiation,
propagation and termination of the immune response (Bhoj &
Chen, 2009; Wertz & Dixit, 2010). Innate immunity represents
the ﬁrst line of defence against invading microorganisms that is
highly effective and conserved throughout evolution (Takeuchi
& Akira, 2010). Pathogen-associated molecular patterns
(PAMPs) serve as a signal for recognition by pattern recognition
receptors (PRRs) in the host (Janeway & Medzhitov, 2002).
Three classes of PRRs have been identiﬁed and extensively
characterized: TOLL-like receptors (TLRs), non-obese diabetic
(NOD)-like receptors (NLRs) and RIG-1-like receptors (RLRs).
Common downstream pathways that are activated by all
these receptors comprise the NF-kB and the mitogen-activated
protein(MAP)kinasesignallingcascades.Ubiquitylationplaysa
fundamental role in the activation of the transcriptional factor
NF-kB, which controls various cellular processes including
immunity, inﬂammation and cell death.The activation of NF-kB
is mediated by canonical and non-canonical pathways. The
classical (canonical) pathway is activated by a wide range
of stimuli including ligation of TNFRI by its cognate ligand
tumour-necrosis factor-a (TNFa), which leads to the phos-
phorylation and degradation of nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor, alpha (IkBa)
resulting in the nuclear translocation of p65 and p50 subunits
and transcriptional activation of target genes (Perkins, 2007).
The phosphorylation of IkBa is regulated by the activation of
IKK complex, which comprises of inhibitor of NF-kB kinase
subunit alpha (IKKa), inhibitor of NF-kB kinase subunit beta
(IKKb) and an essential regulatory subunit NF-kB essential
modulator (NEMO)/IKKg. Phosphorylated IkBa is recognized
by the multi-subunit E3 ubiquitin ligase complex bTrCP, which
catalyzes the conjugation of Lys48-linked ubiquitin chains,
thereby targeting it for proteosomal degradation. The activation
of the IKK complex requires upstream kinases TGFbeta
activated kinase 1 (TAK1) and receptor-interacting protein 1
(RIP1) and involves the contribution of both lysine-linked
and linear ubiquitin chains (Grabbe et al, 2011). Recent
studies have revealed an essential role for the linear ubiquitin
assembly complex (LUBAC) in the regulation of the NF-kB
pathway (Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga
et al, 2011). Mice deﬁcient in the LUBAC component
SHANK-associated RH domain interactor (SHARPIN) suffer
from multi-organ inﬂammation including chronic dermatitis
(Seymour et al, 2007). Apart from being conjugated with linear
ubiquitin chains, NEMO can also bind to linear chains in vivo
with its ubiquitin-binding domain UBAN (ubiquitin binding in
A20-binding inhibitor of NF-kB activation (ABIN) and NEMO)
(Rahighi et al, 2009). The amino acids in the UBAN domain of
NEMO responsible for this interaction are mutated in patients
suffering from X-linked ectodermal dysplasia revealing the
patho-physiological relevance of this interaction (Rahighi et al,
2009). In the absence of inhibitor of apoptosis (IAPs),
stimulation with TNFa often leads to the formation of complex
II where caspase-8 is recruited for its activation leading to
apoptosis (Wang et al, 2008). TNFa-induction can result in
the formation of a ‘necrosome complex’ involving RIP1 and
RIP3 when caspase-8 activation is inhibited and cIAPs are
depleted,leadingtoaformofprogrammedcelldeath(PCD)with
features of necrosis, termed necroptosis (Vandenabeele et al,
2010). Recent studies with various mouse models revealed
a crucial tissue-speciﬁc role of RIP1-RIP3 in regulating
necroptosis-mediated inﬂammation (Bonnet et al, 2011; Duprez
et al, 2011; Gunther et al, 2011; Kaiser et al, 2011; Welz et al,
2011). Further, loss of cIAPs has also been shown to
spontaneously trigger the formation of RIP1, FAS-associated
via death domain (FADD) and caspase-8-containing Ripopto-
some complex in the cytosol (approximately 2MDa complex) to
mediate apoptosis (Feoktistova et al, 2011; Tenev et al, 2011).
The signalling machinery driving necroptosis and its role in
regulating various inﬂammation-associated disorders (like
systemic inﬂammatory response syndrome (SIRS)) is inten-
sively studied in several labs around the world and the readers
are referred to recent excellent reviews (Han et al, 2011;
Vandenabeele et al, 2010).
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proteolytic processing of p100 subunit leading to the formation
of p52 fragment in a NIK-dependent manner (Dejardin, 2006).
cIAP1/2 E3 ligases in combination with TRAF2/3 contribute to
the constitutive polyubiquitylation and proteosomal degrada-
tion of NIK (Vallabhapurapu et al, 2008; Zarnegar et al, 2008).
B-cell-activating factor (BAFF) is one of the well-studied
physiological stimuli known to activate this pathway in B-cells.
Upon binding of BAFF to its receptor, the NIK-degrading
complex is disrupted, resulting in NIK accumulation, which in
turn phosphorylates IKKa (Dejardin, 2006). In both pathways,
theconstantcrosstalkbetweenubiquitylation(ofvariouskinds)
and phosphorylation ﬁne-tunes the signal cascade contributing
to NF-kB activation.
Also, RLRs and some TLRs can activate interferon regulatory
factors (IRF), which act in concert with NF-kB to initiate the
production of interferon-1 as effector molecules. Of note,
ubiquitylation has been reported to play a critical role in the
signalling cascades triggered by all three classes of innate
immune response receptors including NLRs such as NOD2 and
RLRs such as RIG-1. IAP proteins, TRAFs and Pellino proteins
act as ubiquitin ligases that mediate ubiquitylation of critical
substrate proteins (such as IRAKs, RIPs, NEMO) that in turn
leads to activation of TAK1 and/or IKK complexes. Further, IAP
proteins have also been shown to function as direct E3 ubiquitin
ligases of RIP2 contributing to NOD1/2-mediated production of
inﬂammatory cytokines and chemokines (Bertrand et al, 2009).
In addition, ubiquitylation also serves as the signal for the
clearance of pathogenic bacteria in the host cells by xenophagy,
a form of selective autophagy (Kirkin et al, 2009).
Ubiquitin chains attached to substrates can be removed by
DUBs. This removal of ubiquitin molecules by the deubiqui-
tylating enzymes provides a mechanism to dampen the immune
response.SeveralDUBsplayacrucialroleintheimmunesystem
and have been shown to be associated with various immune
disorders summarized below (Fig 2). Cylindromatosis (CYLD)
wasone ofthe ﬁrst DUBsimplicated inNF-kBactivation andhas
been shown to cleave ubiquitin chains required for NF-kB
activation including Lys63-linked and linear chains (Kovalenko
et al, 2003; Reiley et al, 2005). Using an ribonucleic acid (RNA)
interference screen directed against DUBs, CYLD was identiﬁed
as a key regulator of the transcription factor NF-kB (Brummel-
kamp et al, 2003). CYLD contains an ubiquitin hydrolase domain
at its C-terminus that is able to remove ubiquitin chains from
NF-kB signalling molecules including TNF receptor-associated
factor 2 (TRAF2), TNF receptor-associated factor 6 (TRAF6) and
RIP1 (Kovalenko et al, 2003; Reiley et al, 2005). In addition,
CYLD controls the Bcl-3 pathway by de-ubiquitylating Bcl-3,
thereby inhibiting its translocation to the nucleus and the Bcl-3-
mediated transcriptional activation of proliferative genes
(Massoumi et al, 2006). CYLD is mutated in familial cylin-
dromatosis, a hereditary disorder with tumours of the skin
appendages (Bignell et al, 2000). Furthermore, CYLD plays an
important role in the regulation of immune response and
inﬂammation (Sun, 2010). For example, CYLD knockout mice
showdysregulation ofthymocytedevelopmentandactivationof
T-cells associated with bowel inﬂammation and autoimmune
responses (Reiley et al, 2006, 2007; Zhang et al, 2006). CYLD-
deﬁcient mice were reported to display a reduced number of
single positive thymocytes in peripheral T-cells, while early-
stage thymocytes were produced normally (Reiley et al, 2006).
Since CYLD positively regulated lymphocyte-speciﬁc protein-
tyrosine kinase (LCK), a proto-oncogene tyrosine-protein kinase
(SRC)-family protein tyrosine kinase involved in T-cell receptor-
proximal signalling events and thymocyte development (Molina
et al, 1992), CYLD-deﬁcient thymocytes were described to
harbour a defect in the interaction of LCK and zeta-chain-
associated protein kinase 70 (ZAP70) and associated down-
streamsignallingevents(Reileyetal,2006).Furthermore,CYLD
has been reported to act as a crucial regulator of B-cell function
(Sun, 2008). Lack of CYLD expression was reported to lead to
constitutive activation of the canonical NF-kB signalling cascase
in B-cells as shown by higher expression levels of typical NF-kB
target genes (Jin et al, 2007). Furthermore, CYLD-deﬁcient
B-cells have been described to exhibit defects in B-cell
maturation and homeostasis including hyperproduction of
marginal zone B-cells and expansion of B-cells in peripheral
lymphoid organs. Similarly, abnormalities of B-cell function
were reported in mice with a shorter isoform of CYLD (sCYLD),
which is a product of a natural splicing variant of the CYLD gene
lacking the two exons 7 and 8 (Hovelmeyer et al, 2007).
Moreover, CYLD has been implicated in the innate immune
response following bacterial or viral infection. For example,
CYLD has been shown to downregulate the inﬂammatory
response following bacterial infection with Escherichia coli by
negatively regulating the innate immune response via inhibition
of NF-kB signalling (Lim et al, 2008). Accordingly, CYLD-
deﬁcient mice were hypersusceptible to E. coli-mediated
pneumonia with higher rates of mortality (Lim et al, 2008).
In contrast, CYLD-deﬁcient mice were shown to be protected
from Streptococcus pneumoniae-mediated acute lung injury
and lethality (Lim et al, 2007). In this model, CYLD enhanced
acute lung injury and mortality following S. pneumoniae
infection by inhibiting MKK3-p38 kinase-mediated expression
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Figure 2. Deregulation of ubiquitin signalling in immune disorders.
Pathological alterations in ubiquitin signalling pathways can cause various
disorders of the immune system. See text for more details.
548  2012 EMBO Molecular Medicine EMBO Mol Med 4, 545–556 www.embomolmed.orgof plasminogen activator inhibitor-1 (Lim et al, 2007). These
ﬁndings indicate that CYLD can differentially regulate signalling
pathways during the innate immune response to bacterial
infections, depending at least in part on the pathogen. In
addition, CYLD has been shown to act as a negative regulator of
the anti-viral response by removing polyubiquitin chains from
the RNA helicase retinoic acid inducible gene I (RIG-1)
(Friedman et al, 2008; Zhang et al, 2008). RIG-1 activates the
IRF3 signalling pathway to induce interferon type I gene
expression in response to viral infections.
A20 (TNFAIP3) acts as a negative feedback regulator of NF-
kB signalling in response to numerous inﬂammatory stimuli,
including TNFa, IL-1b and pathogens. A20 possesses both E3
ligase and DUB activities and attenuates TNFa signalling by
removing Lys63-linked chains from RIP1 and promotes Lys48-
linked chains for proteosomal degradation (Wertz et al, 2004).
A20-deﬁcient mice show profound activation of the immune
system leading to multiorgan inﬂammation autoimmunity,
characterized by spontaneous production of inﬂammatory
cytokines such as TNFa, IL-1b and IL-6 (Matmati et al,
2011). Further, loss of A20 in keratinocytes leads to hyperker-
atosis, which is a common feature in psoriasis. A20 is associated
with various immune-pathologies in humans such as rheuma-
toid arthritis, systemic lupus erythematousus (SLE), type I
diabetes, Crohn’s disease and psoriasis (Vereecke et al, 2009).
Interestingly, efﬁciency of A20 in myeloid cells has recently
been shown to promote erosive polyarthritis that resembles
rheumatoid arthritis in a mouse model, pointing to a crucial and
cell-speciﬁc function of A20 in the pathogenesis of rheumatoid
arthritis (Matmati et al, 2011). Furthermore, A20 has been
characterized as a susceptibility gene for several autoimmune
disorders (Fig 2) (Vereecke et al, 2009). The roles of CYLD and
A20 in cancer are discussed below.
Though increased NF-kB activity is associated with inﬂam-
mation-associated disorders, recent studies revealed that
inhibition of NF-kB in non-immune cells such as epithelia
leads to spontaneous inﬂammation in a TNFa-dependent
manner (Pasparakis, 2009). However, in chronic inﬂammatory
diseases it has been shown to be quiet useful to reduce the
effects of the pro-inﬂammatory cytokines, especially TNFa.
Anti-TNFa therapeutics (e.g. inﬂiximab) have successfully been
employed in treating several autoimmune disorders including
rheumatoid arthritis, Crohn’s diseases, ulcerative colitis and
SLE. A better understanding of the mechanisms and the tissue-
speciﬁc roles is clearly warranted to pursue therapeutics that
target NF-kB for the treatment of inﬂammatory disorders.
Ubiquitin system in cancer
Numerous evidence indicate that the deregulation of ubiquitin
pathways can directly and indirectly contribute to the devel-
opment and progression of human cancers (Hoeller & Dikic,
2009) (Table 1). One of the most studied aspects is linked to
defective quality control that is essential for the removal of
damaged organelle, misfolded or aggregated proteins. For
example, the deregulation of proteasomal degradation can lead
to the accumulation of mutated or oncogene-encoded proteins.
Perturbing the ﬁne balance between the tumour suppressors
and proto-oncogenes would already predispose normal cells
towards oncogenic transformation. Similarly, accumulation of
damaged mitochondria due to deﬁcient autophagy, for example
Review
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Table 1. E3 ligases and DUBs associated with cancers
Enzymes Targets Cancer association
E3 ligases
MDM2 (HDM2) p53 Over-expressed in multiple cancers including soft tissue sarcoma and lung cancer
(Anderson et al, 1999; Lind et al, 2006; Menin et al, 2006)
CBL RTKs, e.g. FLT3, c-Kit c-Cbl point mutation (Cbl-R420Q) was detected in AML and myoproliferative disorders
(Grand et al, 2009)
FBW7 Myc, Jun, cyclin E, KLF5, Notch1
and TGIF1, Mcl-1
Deleted or mutated in various cancers including T-ALL (Inuzuka et al, 2011;
Wertz et al, 2011)
FBX011 Bcl-6 Deleted or inactivated in diffuse large B-cell lymphoma (Duan et al, 2011)
IAPs Various substrates Over-expressed in various cancers. C-IAP2 is associated with MALT-lymphoma
(Dierlamm et al, 1999; Fulda & Vucic, 2011)
Deubiquitinases
CYLD Various substrates including
RIP1 and Bcl3
Mutated in familial cylindromatosis, inactivated in skin cancers, hepatocellular and
cervical carcinoma (Bignell et al, 2000; Massoumi et al, 2006; Strobel et al, 2002)
USP7 MDM2, PTEN, FOXO4 and others Downregulation reported in non-small cell lung cancer (Masuya et al, 2006)
A20 RIP1, RIP2, TRAF2, TRAF6, UBCH5,
NEMO and others
Frequent inactivation in B-cell lymphomas (Kato et al, 2009)
Usp9x Mcl-1, b-catenin and others Over-expressed in follicular lymphomas and diffuse large B-cell lymphomas,
multiple myeloma (Schwickart et al, 2010)
Usp10 P53 Downregulated in renal cell carcinomas (Yuan et al, 2010)
DUB3 Cdc25A Overexpression in breast cancers (Pereg et al, 2010)
Others
PTEN Promoted ubiquitylation of EGFR
through formation of EGFR–CBL
complex
Inactivated in various cancers (Trotman et al, 2007)
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contribute to oncogenic load by an increase in the oxidative
radical levels and enhanced DNA damage (Mathew & White,
2007). Therefore, alterations in ubiquitylation of numerous
cellular proteins can contribute to tumour formation and
progression. Here, we discuss several examples that are
instructive for molecular medicine.
Several well-known E3 ligases are either aberrantly activated
or display reduced functions in human cancers. For example,
mouse double minute 2 (MDM2) is the E3 ligase that
ubiquitylates the tumour suppressor protein p53 and thus
delivers p53 for proteasomal degradation (Miliani de Marval &
Zhang, 2011). Increased MDM2 activity antagonizes the tumour
suppressor function of p53 resulting in loss of function of p53.
Overexpression of MDM2, for example due to genomic
ampliﬁcation, has been identiﬁed in a variety of human cancers,
for example in soft tissue sarcoma or lung cancer (Anderson
et al, 1999; Lind et al, 2006; Menin et al, 2006). Recently,
TRIP12/ULF was identiﬁed as a novel E3 ligase of Alternate
Reading Frame (ARF of the INK4a locus), a tumour suppressor
that regulates ubiquitin-dependent degradation (Chen et al,
2010). An additional mechanism of how the p53 pathway may
be regulated involves USP10, a DUB that promotes the
stabilization of p53 in response to DNA damage in an ATM-
dependent signalling pathway (Yuan et al, 2010). After DNA
damage, USP10 is stabilized by ATM-mediated phosphorylation
andapoolofUSP10translocatestothenucleustodeubiquitylate
and activate p53 (Yuan et al, 2010). Notably, downregulation of
USP10 expression was found in a high percentage of renal cell
carcinomas, which are known to have few p53 mutations (Yuan
et al, 2010), indicating that USP10 downregulation may
represent an alternative mechanism of inactivating the p53
pathway in cancers.
Casitas B-lineage lymphoma (CBL) is another well-studied
ubiquitin E3 ligase that has been implicated in cancer
pathogenesis (Lipkowitz & Weissman, 2011). CBL is involved
in the downregulation of receptor tyrosine kinases, e.g. of FLT3
or c-KIT, via multiple ubiquitylation events (Schmidt & Dikic,
2005). Deregulation of CBL has been identiﬁed in various
cancers including acute myeloid leukaemia (AML), lymphoma
and gastric carcinoma and has been linked to insufﬁcient
termination of receptor tyrosine kinase signalling (Casas et al,
2003). For example, CBL was found to be involved in the
regulation of FLT3 signalling in AML. c-Cbl has been shown to
physically interact with FLT3 and to undergo tyrosine
phosphorylation upon binding of FLT3-ligand (Sargin et al,
2007). The involvement of c-Cbl in Flt3 signalling was further
conﬁrmed by overexpression of a dominant-negative form of
c-Cbl (Cbl-70Z) that blocked FLT3-ligand-induced FLT3 ubiqui-
tylation and internalization (Sargin et al, 2007). Interestingly,
a c-Cbl point mutation (Cbl-R420Q) was detected in primary
AML cells that similarly inhibited FLT3 ubiquitylation (Sargin
et al, 2007). Also, CBL mutations were identiﬁed in myelopro-
liferative disorders (Grand et al, 2009). Of note, mutant
variants of CBL that are defective in their E3 ligase activity
wereshowntopromotec-KIT-orFLT3-mediatedtransformation
(Bandi et al, 2009).
Thestemcellfactor(SCF)complexisamulti-subunitubiquitin
ligase complex composed of S-phase kinase-associated protein 1
(SKP1), CUL1 and a variable, substrate-speciﬁc F-box protein
(Cardozo & Pagano, 2004). F-box and WD repeat domain-
containing 7 (FBW7), a F-box protein, is the substrate-speciﬁc
component of this composite E3 ligase (Cardozo & Pagano,
2004). FBW7 binds to phospho-degrons, i.e. phosphorylated
regions of the substrate proteins, leading to their polyubiqui-
tylation and subsequent proteasomal degradation (Cardozo &
Pagano, 2004). Target proteins of FBW7 comprise various
oncogenes as well as key signalling mediators of cell growth and
proliferation, i.e. Myc, Jun, cyclin E, krueppel-like factor 5
(KLF5), Notch homolog 1, translocation-associated (Droso-
phila) (Notch1) and TGFb-induced factor 1 (TGIF1) (Cardozo &
Pagano, 2004). Since overexpression of several FBW7 target
proteins such as Jun, Myc or Notch 1 results in increased cell
death in addition to elevated proliferation, it has been unclear
until recently how FBW7-deﬁcient cells can evade programmed
cell death under these conditions. Therefore, the recent
identiﬁcation of MCL1 as a FBW7 target protein has provided
a plausible explanation for this open question (Inuzuka et al,
2011; Wertz et al, 2011). MCL1 belongs to the pro-survival
proteins of the BCL2 family that block mitochondrial apoptosis
(Adams & Cory, 2007). Furthermore, sensitivity to microtubule-
targeted agents such as Taxol and vincristine has been
demonstrated to be regulated by MCL1 and FBW7 (Wertz
et al, 2011). During mitotic arrest, MCL1 protein levels decline
post-translationally through FBW7-mediated destruction via the
proteasome (Wertz et al, 2011). The interaction of MCL1 with
FBW7is promoteduponphosphorylation ofMCL1inmitotically
arrested cells, enhancing polyubiquitylation of MCL1 and its
subsequent proteasomal degradation (Wertz et al, 2011).
Findings in primary tumour samples showing elevated MCL1
levels and concomitant FBW7 inactivation underscored the
rolesofboth proteinsin oncogenesis(Inuzuka etal, 2011; Wertz
et al, 2011). Furthermore, probable ubiquitin carboxyl-terminal
hydrolase FAF-X (USP9X) was recently identiﬁed as a MCL1-
speciﬁc DUB that removes ubiquitin from the anti-apoptotic
protein MCL1, thereby promoting the stability of MCL1 and
opposing apoptosis (Schwickart et al, 2010). USP9X binds
directly to MCL1 and de-ubiquitylates Lys 48-linked ubiquitin
chainsthatlabelMCL1forproteasomaldegradation(Schwickart
et al, 2010). Of note, overexpression of USP9X correlates with
increased MCL1 protein expression in human cancers, i.e. in
follicular lymphomas and diffuse large B-cell lymphomas
(Schwickart et al, 2010). In patients with multiple myeloma,
increased expression of USP9X correlated with a poor prognosis
(Schwickart et al, 2010).
Interestingly, aurora kinase A has recently been reported to
stabilize N-Myc by competing for FBW7-binding (Otto et al,
2009). This implies that aurora kinase A inhibitors could
suppress proliferation by restoring FBW7-mediated degradation
of c-Myc. Loss of FBW7 is frequently detected in various
malignancies, including breast or colon cancer and T-cell acute
lymphoblastic leukaemia (Crusio et al, 2010). Genetic inactiva-
tion of FBW7 in mouse T-cells has been shown to promote
lymphomagenesis (Onoyama et al, 2007), validating FBW7 as a
Review
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point out that the gene-encoding another F-box containing
protein FBXO11 is deleted or inactivated in diffuse B-cell
lymphomas (DLBCL) and Bcl-6 has recently been identiﬁed as a
target protein. Loss of FBX011 leads to increased stabilization of
Bcl-6, thereby contributing to pathogenesis of human B-cell
lymphomas (Duan et al, 2012).
Phosphatase and tensin homologue deleted in chromosome
10 (PTEN) is a tumour suppressor protein that is inactivated in
manyhumancancers(Georgescu,2010).PTENiswellknownas
a phosphatidylinositol 3,4,5-triphosphatase that negatively
regulates the PIK/Akt/mTOR cascade (Georgescu, 2010). More
recently, PTEN has been shown to be also involved in ubiquitin
signalling. It was reported that PTEN promotes ubiquitylation
and downregulation of receptor tyrosine kinases such as
epidermal growth factor receptor (EGFR) by enhancing the
formation of the EGFR–CBL complex (Vivanco et al, 2010).
Thus, by targeting EGFR for degradation, PTEN promotes the
termination of EGFR signalling. Furthermore, PTEN itself is
regulated by ubiquitin-dependent mechanisms in cancer.
Monoubiquitylation of PTEN has been demonstrated to be
required for its nuclear localization and tumour suppression
(Trotman et al, 2007). Lysine residue K289 was identiﬁed as one
of the major monoubiquitylation sites that are essential for
PTEN import (Trotman et al, 2007). Interestingly, the PTEN
lysine mutant K289E, which retains catalytic activity but cannot
be monoubiquitylated, is defective in nuclear import and
accumulation (Trotman et al, 2007). This lysine mutant of
PTEN has been associated with Cowden syndrome, a cancer-
susceptibility syndrome with inherited PTEN mutation
(Trotman et al, 2007).
Furthermore, ubiquitylation regulates PTEN stability. The
HECT-domain protein neural precursor cell expressed, devel-
opmentally down-regulated 4-1 (NEDD4-1) has been identiﬁed
as the E3 ligase that catalyzes PTEN polyubiquitylation and
triggers proteasomal degradation of PTEN (Wang et al, 2007).
Importantly, high levels of NEDD4-1 were detected in tumour
samples of various malignancies with low PTEN protein
expression on normal genetic background of PTEN (Wang
et al, 2007). This implies that upregulation of NEDD4-1 in
cancerscansuppressPTENonapost-translational level.In turn,
the activity of NEDD4-1 is opposed by the tyrosine kinase RAK.
It has been shown that RAK physically interacts with PTEN and
phosphorylates PTEN on Tyr336, thereby protecting it from
ubiquitin-mediated degradation (Yim et al, 2009). Silencing of
RAK led to increased binding of PTEN to NEDD4-1 and
enhanced polyubiquitylation and degradation of PTEN (Yim
et al, 2009). The de-ubiquitylation enzyme herpes-virus-
associated ubiqutin-speciﬁc protease (HAUSP, also known as
USP7) catalyzes the de-ubiquitylation of both MDM2 and p53
and can thereby modify the link between MDM2 and p53.
Downregulation of HAUSP in human cancers therefore leads to
inactivation of the p53 signalling pathway, an event that has
been reported, e.g. in non-small cell lung carcinoma (Masuya
etal, 2006). Further, HAUSP alsoregulatesthe de-ubiquitylation
of PTEN thereby favouring its exclusion from the nucleus
(Song et al, 2008).
Another interesting class of E3 ligases found to be directly
associated with cancers include IAP proteins that have been
showntobehighlyexpressedinseveralhumancancers(Fulda&
Vucic, 2012). For example, c-IAP1 can function as an oncogene
in hepatocellular carcinoma and is part of 11q21-q23 amplicons
in human cancers (Zender et al, 2006). In multiple myeloma,
deletions of c-IAP1 and cellular inhibitor of apoptosis 2 (c-IAP2)
were identiﬁed that lead to stimulation of the non-canonical
NF-kB pathway (Annunziata et al, 2007; Keats et al, 2007). This
ﬁnding is consistent with the known function of c-IAP1 and
c-IAP2 as E3 ligases that constitutively trigger degradation of
NIK via the proteasome (Vallabhapurapu et al, 2008; Zarnegar
et al, 2008). Further, gene rearrangements t(11;18) (q21;21)
leading to the formation of fusion protein c-IAP2/MALT are
associated with 50% of mucosa associated lymphatic tissue
(MALT) lymphomas (Dierlamm et al, 1999). The chimeric
protein constitutively activated NF-kB contributing to B-cell
transformation. Recently, IAP proteins have also been shown to
regulate tumour cell migration by functioning as the direct E3
ubiquitin ligases of the RhoGTPase Rac1 (Oberoi et al, 2012).
BesidesE3ligases,deregulationofde-ubiquitylationenzymes
(DUBs) can contribute to tumorigenesis by stabilizing onco-
proteins or proteins that promote proliferation or block cell
death. For example, the de-ubiquitylation enzyme CYLD
represents a well-known tumour suppressor. Mutation in CYLD
is found in familial cylindromatosis, a hereditary disorder with
skin tumours (Bignell et al, 2000). Furthermore, decreased or
absent expression of CYLD occurs in other skin cancers, for
example basal cell carcinoma, squamous cell carcinoma of
the skin as well as hepatocellular and cervical carcinoma
(Massoumi et al, 2006; Strobel et al, 2002). Recent studies
revealed that A20 can also function as a tumour suppressor in
lymphomas. Frequent inactivation of A20 is detected primarily
in B-cell lymphomas leading to uncontrolled NF-kB signalling
and tumorigenesis (Kato et al, 2009). Further, SCF ligase, which
is responsible for degradation of IkBa, has recently been
reported to be mutated in a high number of human cancers
(Lee et al, 2009), thereby contributing to aberrant NF-kB
signalling in human malignancies.
Finally, oncogenes have also been shown to be activated by
non-degradative ubiquitylation. An example for such non-
degradative ubiquitin signalling in cancer is lysine 63-linked
polyubiquitylation of Akt via TRAF6, which facilitates mem-
brane localization of Akt and its subsequent activation (Yang
et al, 2009). This mechanism of Akt ubiquitylation represents a
step that is involved in oncogenic Akt activation, since human
cancer-associated mutant variants of Akt showed elevated Akt
ubiquitylation, thereby promoting its membrane localization,
phosphorylation and activation (Yang et al, 2009).
Therapeutic perspective of targeting the
ubiquitin system
The growing understanding of the molecular mechanisms and
biological consequences of the ubiquitin system provides the
basis for the development of drug-like inhibitors of enzyme
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bortezomib in treating multiple myeloma facilitated faster
FDA approval in 2003 and there are several proteosomal
inhibitors in various stages of clinical development (Table 2). In
2006, bortezomib was approved for treating mantel cell
lymphoma. Bortezomib is also pursued in clinical trials in
combination with other chemotherapeutic drugs for treating
solid tumours. Furthermore, bortezomib showed synergistic
activities together with the death receptor ligand TNF-related
apoptosis-inducing ligand (TRAIL) to trigger apoptosis in
various human cancer (Naumann et al, 2011; Sayers & Murphy,
2006; Unterkircher et al, 2011). Following bortezomib, new
classes of inhibitors including carﬁlzomib, Salinospororamidine
A (NPI-002), CEP-18770, PR-957 and Ritonavir are in various
stages of preclinical/clinical development (Ruschak et al, 2011).
The novel proteasome inhibitors like Carﬁlzomib differ from
bortezomib primarily in targeting the speciﬁc protease activity
of the 20S proteasome (Ruschak et al, 2011).
Since the substrate selectivity of the ubiquitin system
primarily resides in the speciﬁcity of the several hundreds of
E3 ligases, these enzymes constitute promising targets for
therapeutic intervention. One prominent target is MDM2, as its
inhibition results in the activation of the p53 pathway, thereby
leading to cell cycle arrest and cell death. Accordingly, small-
molecule MDM2 inhibitors have been developed that speciﬁ-
cally target the E3 ligase activity of MDM2 (Yang et al, 2005).
HLI98 represents a small-molecule MDM2 inhibitor of the ﬁrst
generation that blocks the E3 ligase activity of MDM2 leading to
stabilization of p53, p53-dependent transcription and induction
of cell death (Di et al, 2011; Yang et al, 2005). A structural study
conﬁrmed the mode of action of small-molecule MDM2
antagonists nutlins showing that these compounds bind
MDM2 via the p53-binding pocket, thereby preventing its
interaction with p53 (Vassilev et al, 2004). RITA (2,5 bis(5-
hydroxy-methyl-2thienyl)furan) targets the interaction between
p53 and MDM2. However, both RITA and nutlins are shown to
exhibit off-target effects. Currently, Johnson and Johnson
reported benzodiazepinedione inhibitors that selectively kill
p53 wild-type cells (Koblish et al, 2006) and a phase I clinical
trial with the lead compound JNJ-26854165 has just been
completed.
S-phase kinase-associated protein 2 (SKP2) is another E3
ligase that is considered as a promising cancer drug target. SKP2
is a substrate-speciﬁc subunit of the SCF ligase complex that
targets cell cycle regulators such as p27 for proteasomal
degradation (Bedford et al, 2011). Inhibition of SKP2 is expected
to result in increased levels of the cell cycle inhibitor p27,
restraining cell proliferation. Indeed, targeting SKP2 has been
reported to lead to p27- and SKP2-mediated cell cycle arrest
(Chen et al, 2008). The discovery of NEDD8 modiﬁcation of
cullins for E3 ligase activity prompted millenium pharmaceutics
to develop a NEDD-8-speciﬁc E1 inhibitor (ML4924). ML4924 is
currently in phase I clinical trials for treatment of hematologic
malignancies and melanoma.
Inhibitor of apoptosis proteins represent another well-known
family of E3 ligases that are involved in the regulation of cell
death and NF-kB signalling. Since IAP proteins are expressed at
aberrantly high levels in various cancers and have been
associated with poor treatment response, they are currently
undergoing evaluation as cancer drug targets (Straub, 2011).
Accordingly, several approaches to neutralize IAP expression
and function have been developed in recent years which are
currently tested in early clinical trials (Fulda & Vucic, 2012). For
example, Smac mimetics that bind to IAP proteins such as X-
linked inhibitor of apoptosis protein (XIAP) and cIAPs in a
manner similar to the endogenous mitochondrial protein Smac
have been shown to neutralize IAP-imposed inhibition of
caspases and to trigger their autoubiquitylation and degradation
(Fulda & Vucic, 2012). Treatment of tumour cells with Smac
mimetic compounds has been shown to sensitize tumour cells
both in vitro and in vivo and many of these compounds are
already in clinical trials (Fulda & Vucic, 2012; Table 2).
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Table 2. Anti-cancer drugs in clinical trials targeting the ubiquitin machinery
Drugs Properties Source Stage of clinical development
Bortezomib 20S proteasome inhibitor Millennium Pharmaceuticals Approved for multiple myeloma,
mantle cell lymphoma
MLN9708 Oral proteasome inhibitor Millennium Pharmaceuticals Phase I
Carfilzomib/PR-171 Proteasome inhibitor derived from epoxomycin Onyx Pharmaceuticals Phase I/II
NPI-0052 Irreversible 20S proteasome inhibitor Nereus Pharmaceuticals Phase I
CEP-18770 Orally active proteasome inhibitor Ethical Oncology Science Phase I
ONYX 0912 Oral proteasome inhibitor Onyx Pharmaceuticals Phase I
RO5503781,
RO5045337
Small molecule MDM2 antagonist Hoffmann-La Roche Phase I
MLN4924 NEDD8 inhibitor Millenium Pharmaceuticals Phase I
JNJ-26854165 MDM2 inhibitor Johnson & Johnson Pharmaceutical
Research & Development, LLC
Phase I
GDC-0152 IAP inhibitor Genentech Phase I
AT-406 IAP inhibitor Ascenta Therapeutics Phase I
LCL-161 IAP antagonist Novartis Pharmaceuticals Phase I
AEG-35156 XIAP antagonist Aegera Therapeutics Phase I/II
TL32711 IAP antagonist TetraLogic Pharmaceuticals Phase I/II
HGS1029 IAP antagonist Human Genome Sciences Phase I
Source: www.clinicaltrials.gov.
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made to target the E1 activation and ubiquitin-UBD interactions.
PYR-41 was found in a small-molecule screen as an inhibitor of
E1 activity though no effects on anti-tumour activity were
reported (Yang et al, 2007). Ubistatins are the ﬁrst class of
compounds identiﬁed to disrupt the interaction between
ubiquitin and the ubiquitin-binding domains (Verma et al,
2004).However,theyarenotpursuedfurther,astheyareunable
to penetrate cell membranes. Despite the existing problems,
these pilot studies have already opened up an avenue for
targeting protein–protein interactions to regulate ubiquitin
signalling. Improved structural analysis accompanied by a
better understanding of the molecular mechanisms driving the
function of ubiquitylating enzymes will help to develop more
selective inhibitors.
Conclusions and future perspectives
The last decade has seen a phenomenal surge in the interest on
ubiquitin signalling which has launched PTMs via ubiquitin
moieties as a central regulator of virtually all cellular processes
(Grabbe et al, 2011). The clinical success of bortezomib has
proved the importance of targeting the UPS machinery and
several proteasome inhibitors are being currently pursued in
clinical trials. Efforts to target conjugation enzymes (E1-3) have
been pursued with some success. There are a growing number
of E3 ligases being implied in various tumours and drugs
targeting some of these enzymes like IAP antagonists or MDM2
inhibitors are already in clinical trials. The role of NF-kB in the
pathology of autoimmune disorders has been well established
and efforts have been made to circumvent uncontrolled
inﬂammation by attenuating cytokine responses. Inﬂiximab is
a successful drug of this kind and more effective inhibitors are
being developed to inhibit downstream signalling.
Like in many cases, these drugs exhibit side effects and only
further insights into the regulation of signal transduction
pathways that are deregulated in cancer and autoimmune
disorders will allow us to develop more speciﬁc therapeutic
agents.Studiesinvolvinginvivomousediseasemodelscontinue
toprovetheirworth albeitlimitations. Therecentadvancements
in mass spectrometric analyses and structural studies have
signiﬁcantly improved our understanding of the ubiquitin
machinery. Only in 2006, we have uncovered the ligases
responsible for synthesizing linear ubiquitin chains and
quickly in vivo studies have revealed their importance for
immunity and inﬂammation. The role of atypical ubiquitin
chains and their role in regulating normal physiology is
an exciting area of research and unveiling the complex cross
talks between ubiquitylation and other PTMs will continue to
be a challenging issue, as exempliﬁed by recent ﬁndings
that phosphorylation controls the ubiquitin-dependent selective
autophagy processes (Matsumoto et al, 2011; Wild et al, 2011).
Interdisciplinary approaches have substantially enhanced our
understanding of the ubiquitin machinery in the last years and
there is no doubt that drugs targeting the ubiquitin machinery
either alone and in combination with others will be saviours of
the future.
The authors declare that they have no conﬂict of interest.
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